Polaris Pharmaceuticals is evaluating its lead therapeutic protein—pegargiminase, a novel targeted cancer therapy that depletes circulating arginine—in combination with standard chemotherapies ...

These findings offer the promise of new treatments. By disrupting arginine metabolism, the researchers successfully restored CD8 + T cell activity and slowed tumor growth in preclinical models.

They also found that disrupting arginine metabolism could help restore the activity of the T cells and slow tumour growth. “These findings highlight the potential of targeting arginine metabolic ...

These findings offer the promise of new treatments. By disrupting arginine metabolism, the researchers successfully restored CD8 + T cell activity and slowed tumor growth in preclinical models.

These findings offer the promise of new treatments. By disrupting arginine metabolism, the researchers successfully restored CD8+ T cell activity and slowed tumor growth in preclinical models. Based ...

The top-line results from the ATOMIC-Meso study are nothing short of tremendous leveraging a novel area of cancer metabolism for patients by targeting arginine, specifically in non-epithelioid ...

Marlieke Visser; Walter J. Paulus; Mechteld A.R. Vermeulen; Milan C. Richir; Mariska Davids; Willem Wisselink; Bas A.J.M. de Mol; Paul A.M. van Leeuwen ...

Boosting Breakthrough That Helps Control Hunger Cravings Naturally—Without Stimulants, Crashes, or Calorie-Starvation ...